Cascade of Refusal—What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa?

Current HIV/AIDS Reports

Volumn 13, Issue 2, 2016, Pages 125-130

  Katz, Ingrid T ^a,b,c   Bangsberg, David R ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiretroviral medications; ART refusal; Global epidemic; HIV prevention; HIV AIDS; Point of testing; Review; Science of prevention; Treatment refusal

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; CONCEPTUAL FRAMEWORK; COUNSELING; DECISION MAKING; HEALTH CARE NEED; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTIVATION; POINT OF CARE TESTING; PREVENTIVE MEDICINE; REVIEW; SOCIAL ASPECT; SOCIAL BEHAVIOR; TREATMENT REFUSAL; SOCIAL STIGMA;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; DECISION MAKING; HIV INFECTIONS; HUMANS; SOCIAL STIGMA; TREATMENT REFUSAL;

EID: 84958767990     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-016-0309-9     Document Type: Review

References (77)

1. Joint United Nations Programme on HIV/AIDS (UNICEF). How AIDS changed everything—MDG 6: 15 years, 15 lessons of hope from the AIDS response. Geneva, Switzerland. 2015. http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. Accessed 22 August 2015.
2. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Eng J Med. 2015. doi:10.1056/NEJMoa1506816. A trial of over 4000 patients in 35 countries, showed that the risk of death, a serious AIDS-related event, or a serious non–AIDS-related event was 57% lower among those treated early than among those treated when the CD4+ cell count decreased to 350 cells per cubic millimeter. INSIGHT and TEMPRANO confirm previous observational studies and add important new evidence that advances our knowledge of the risks and benefits of early ART in patients with CD4+ cell counts of more than 500 cells per cubic millimeter.
3. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Eng J Med. 2015. doi:10.1056/NEJMoa1507198. This study involved over 2000 patients in the Ivory Coast, and showed that early ART initiation was associated with a 44% lower risk of death or severe HIV-related illness than was ART initiated according to prevailing World Health Organization criteria.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi:10.1056/NEJMoa1105243.
5. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: 2015. Available from: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1. Accessed: Accessed.
6. Beyrer C, Birx DL, Bekker L-G, Barré-Sinoussi F, Cahn P, Dybul MR, et al. The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. Lancet. 2015;386(9993):505–7.
7. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis. 2015;60(7):1120–7. doi:10.1093/cid/ciu1137.
8. Piot P, Abdool Karim SS, Hecht R, Legido-Quigley H, Buse K, Stover J, et al. Defeating AIDS—advancing global health. Lancet. 2015;386(9989):171–218. doi:10.1016/S0140-6736(15)60658-4.
9. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51(2):135–9.
10. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, et al. Who starts antiretroviral therapy in Durban, South Africa?… not everyone who should. Aids. 2010;24 Suppl 1:S37–44. doi:10.1097/01.aids.0000366081.91192.1c.
11. Losina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The “ART” of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010;5(3):e9538. doi:10.1371/journal.pone.0009538.
12. Tayler-Smith K, Zachariah R, Massaquoi M, Manzi M, Pasulani O, van den Akker T, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010;104(5):313–9. doi:10.1016/j.trstmh.2010.01.007.
13. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15 Suppl 1:1–15. doi:10.1111/j.1365-3156.2010.02508.x.
14. Ingle SM, May M, Uebel K, Timmerman V, Kotze E, Bachmann M, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. Aids. 2010;24(17):2717–25. doi:10.1097/QAD.0b013e32833fb71f.
15. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr. 2013;63(2):e64–71. doi:10.1097/QAI.0b013e31828af5a6. This study used a sampling-based approach to understand uptake of ART among eligible patients at a scale-up clinic in Uganda. The authors found the rate and total uptake of ART was neither optimally fast nor complete.
16. Gwadz M, Cleland CM, Applegate E, Belkin M, Gandhi M, Salomon N, et al. Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention. AIDS Behav. 2015;19(10):1801–17. doi:10.1007/s10461-015-1054-6.
17. McNairy ML, Gachuhi AB, Lamb MR, Nuwagaba-Biribonwoha H, Burke S, Ehrenkranz P, et al. The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implement Sci. 2015;10:101. doi:10.1186/s13012-015-0291-4.
18. Siedner MJ, Santorino D, Lankowski AJ, Kanyesigye M, Bwana MB, Haberer JE, et al. A combination SMS and transportation reimbursement intervention to improve HIV care following abnormal CD4 test results in rural Uganda: a prospective observational cohort study. BMC Med. 2015;13:160. doi:10.1186/s12916-015-0397-1.
19. Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sanne I. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014;9(10):e110252. doi:10.1371/journal.pone.0110252.
20. Kranzer K, Zeinecker J, Ginsberg P, Orrell C, Kalawe NN, Lawn SD, et al. Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One. 2010;5(11):e13801. doi:10.1371/journal.pone.0013801.
21. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012;17(12):1509–20. doi:10.1111/j.1365-3156.2012.03089.x.
22. McGrath N, Glynn JR, Saul J, Kranzer K, Jahn A, Mwaungulu F, et al. What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public Health. 2010;10:601. doi:10.1186/1471-2458-10-601.
23. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC. Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav. 2014;18(7):1199–223. doi:10.1007/s10461-014-0729-8.
24. Siedner MJ, Lankowski A, Tsai AC, Muzoora C, Martin JN, Hunt PW, et al. GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. Aids. 2013;27(9):1503–8. doi:10.1097/QAD.0b013e32835fd873.
25. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav. 2010;14(4):778–84. doi:10.1007/s10461-009-9533-2.
26. Chimbindi N, Bor J, Newell ML, Tanser F, Baltusen R, Hontelez J, et al. Time and money: the true costs of health care utilization for patients receiving ‘free’ HIV/TB care and treatment in rural KwaZulu-Natal. J Acquir Immune Defic Syndr. 2015. doi:10.1097/QAI.0000000000000728.
27. Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007;97(7):524–9.
28. Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, Muyindike WR, et al. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 2013;10(1):e1001369. doi:10.1371/journal.pmed.1001369. Researchers indentified people to interview by using “tracking lists” from HIV/AIDS care clinics in the three countries and found the main unintentional reason for missing clinic visits was a conflicting demand on the patients’ time, which was often unexpected and for complex reasons, such as caring for a dying relative, going to a funeral, or traveling to work. These findings indicate that absences may be unintentional as well as intentional and that the reasons are complex and can change over time.
29. Naik R, Doherty T, Jackson D, Tabana H, Swanevelder S, Thea DM, et al. Linkage to care following a home-based HIV counselling and testing intervention in rural South Africa. J Int AIDS Soc. 2015;18:19843. doi:10.7448/IAS.18.1.19843.
30. Negin J, Wariero J, Mutuo P, Jan S, Pronyk P. Feasibility, acceptability and cost of home-based HIV testing in rural Kenya. Trop Med Int Health. 2009;14(8):849–55. doi:10.1111/j.1365-3156.2009.02304.x.
31. Menzies N, Abang B, Wanyenze R, Nuwaha F, Mugisha B, Coutinho A, et al. The costs and effectiveness of four HIV counseling and testing strategies in Uganda. Aids. 2009;23(3):395–401. doi:10.1097/QAD.0b013e328321e40b.
32. Naik R, Tabana H, Doherty T, Zembe W, Jackson D. Client characteristics and acceptability of a home-based HIV counselling and testing intervention in rural South Africa. BMC Public Health. 2012;12:824. doi:10.1186/1471-2458-12-824.
33. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012;9(12):e1001351. doi:10.1371/journal.pmed.1001351.
34. Helleringer S, Kohler HP, Frimpong JA, Mkandawire J. Increasing uptake of HIV testing and counseling among the poorest in sub-Saharan countries through home-based service provision. J Acquir Immune Defic Syndr. 2009;51(2):185–93. doi:10.1097/QAI.0b013e31819c1726.
35. Mutale W, Michelo C, Jurgensen M, Fylkesnes K. Home-based voluntary HIV counselling and testing found highly acceptable and to reduce inequalities. BMC Public Health. 2010;10:347. doi:10.1186/1471-2458-10-347.
36. Sekandi JN, Sempeera H, List J, Mugerwa MA, Asiimwe S, Yin X, et al. High acceptance of home-based HIV counseling and testing in an urban community setting in Uganda. BMC Public Health. 2011;11:730. doi:10.1186/1471-2458-11-730.
37. Dalal W, Feikin DR, Amolloh M, Ransom R, Burke H, Lugalia F, et al. Home-based HIV testing and counseling in rural and urban Kenyan communities. J Acquir Immune Defic Syndr. 2013;62(2):e47–54. doi:10.1097/QAI.0b013e318276bea0.
38. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572–9. doi:10.1016/S0140-6736(11)61052-0.
39. Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010;376(9734):33–40. doi:10.1016/S0140-6736(10)60894-X.
40. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet. 2012;380(9845):889–98. doi:10.1016/S0140-6736(12)60730-2.
41. Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8(2):e56088. doi:10.1371/journal.pone.0056088.
42. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Community-based Adherence Clubs for the management of stable antiretroviral therapy patients in Cape Town, South Africa: a cohort study. J Acquir Immune Defic Syndr. 2015. doi:10.1097/QAI.0000000000000863.
43. Holmes CB, Sanne I. Changing models of care to improve progression through the HIV treatment cascade in different populations. Curr Opin HIV AIDS. 2015;10(6):447–50. doi:10.1097/COH.0000000000000194.
44. Ramovha RKL, Lebese RT, Shilubane HN. The psychological experience of HIV and AIDS by newly diagnosed infected patients at hospital A of Vhembe District, Limpopo Province. J AIDS Clinic Res. 2012;S1:006. doi:10.4172/2155-6113.S1-006.
45. Abdool Karim SS. Stigma impedes AIDS prevention. Nature. 2011;474(7349):29–31. doi:10.1038/474029a.
46. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640. doi:10.7448/IAS.16.3.18640.
47. Gilbert L, Walker L. ‘My biggest fear was that people would reject me once they knew my status…’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa. Health Soc Care Community. 2010;18(2):139–46. doi:10.1111/j.1365-2524.2009.00881.x.
48. Tsai AC, Bangsberg DR, Kegeles SM, Katz IT, Haberer JE, Muzoora C, et al. Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med. 2013;46(3):285–94. doi:10.1007/s12160-013-9514-6.
49. Takada S, Weiser SD, Kumbakumba E, Muzoora C, Martin JN, Hunt PW, et al. The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med. 2014;48(1):26–37. doi:10.1007/s12160-013-9576-5.
50. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. Aids. 2011;25(17):2177–81. doi:10.1097/QAD.0b013e32834b6464.
51. Curran K, Ngure K, Shell-Duncan B, Vusha S, Mugo NR, Heffron R, et al. If I am given antiretrovirals I will think I am nearing the grave’: Kenyan HIV serodiscordant couples’ attitudes regarding early initiation of antiretroviral therapy. Aids. 2014;28(2):227–33. doi:10.1097/QAD.0000000000000025. Researchers interviewed serodiscordant couples in Kenya to understand attitudes toward initiation of ART at higher CD4+ cell counts and highlights the fact that many participants felt ART was the final stage before death.
52. Gamble T MM, Talley J, Dusara P, Maliwichi M, Kumarasamy N, Batani J, Matchere F, Calvet G, Brum T, Dhayarkar S, Chariyalertsak S, Lira RA, Mills LA, Govender S, Badal-Faesen S, Li X, Cohen M. Acceptance of ART in the delay arm after notification of interim study results: data from HPTN 052. 20th Conference on Retrovirus and Opportunistic Infections; Atlanta2013.
53. Abdool Karim Q, Dellar RC, Bearnot B, Werner L, Frohlich JA, Kharsany AB, et al. HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav. 2015;19(2):322–9. doi:10.1007/s10461-014-0951-4.
54. Ojikutu B, Nnaji C, Sithole-Berk J, Bogart LM, Gona P. Barriers to HIV testing in black immigrants to the U.S. J Health Care Poor Underserved. 2014;25(3):1052–66. doi:10.1353/hpu.2014.0141.
55. Houston E, McKirnan DJ, Cervone D, Johnson MS, Sandfort TG. Assessing treatment motivation among patients receiving antiretroviral therapy: a multidimensional approach. Psychol Health. 2012;27(6):674–87. doi:10.1080/08870446.2011.618536.
56. Jurgensen M, Sandoy IF, Michelo C, Fylkesnes K, Group ZS. Effects of home-based voluntary counselling and testing on HIV-related stigma: findings from a cluster-randomized trial in Zambia. Soc Sci Med. 2013;81:18–25. doi:10.1016/j.socscimed.2013.01.011.
57. Coates TJ, Kulich M, Celentano DD, Zelaya CE, Chariyalertsak S, Chingono A, et al. Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health. 2014;2(5):e267–77. doi:10.1016/S2214-109X(14)70032-4.
58. Matthews LT, Moore L, Crankshaw TL, Milford C, Mosery FN, Greener R, et al. South Africans with recent pregnancy rarely know partner’s HIV serostatus: implications for serodiscordant couples interventions. BMC Public Health. 2014;14:843. doi:10.1186/1471-2458-14-843.
59. Katz ID, J; Bogart, LM; Leone, D; Courtney, I; Tshabalala, G; Fitzmaurice, GM; Bangsberg, DR; Orrell, C; Gray, G. Treatment refusal in South Africa in an era of expanded antiretroviral therapy availability—a cross-sectional multi-site study. International Association of Providers of AIDS Care; Miami, FL2015.
60. Okeke NL, Ostermann J, Thielman NM. Enhancing linkage and retention in HIV care: a review of interventions for highly resourced and resource-poor settings. Curr HIV/AIDS Rep. 2014;11(4):376–92. doi:10.1007/s11904-014-0233-9.
61. Shen L, Condit CM, Wright L. The psychometric property and validation of a fatalism scale. Psychol Health. 2009;24(5):597–613. doi:10.1080/08870440801902535.
62. Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA, et al. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015;19(4):704–14. doi:10.1007/s10461-014-0920-y. This is our first study defining treatment refusal in a South African context.
63. Christopoulos KA, Olender S, Lopez AM, Lekas HM, Jaiswal J, Mellman W, et al. Retained in HIV care but not on antiretroviral treatment: a qualitative patient-provider dyadic study. PLoS Med. 2015;12(8):e1001863. doi:10.1371/journal.pmed.1001863. This manuscript is a qualitative study focused on understanding ART refusal. Specifically, ART as a signifier of AIDS and approaching death is viewed as negative, not a life saver.
64. Siedner MJ, Lankowski A, Haberer JE, Kembabazi A, Emenyonu N, Tsai AC, et al. Rethinking the “pre” in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One. 2012;7(6):e39894. doi:10.1371/journal.pone.0039894.
65. Vansteenkiste M, Sheldon KM. There’s nothing more practical than a good theory: integrating motivational interviewing and self-determination theory. Br J Clin Psychol. 2006;45(Pt 1):63–82. doi:10.1348/014466505X34192.
66. Lundahl B, Burke BL. The effectiveness and applicability of motivational interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol. 2009;65(11):1232–45. doi:10.1002/jclp.20638.
67. Goggin K, Gerkovich MM, Williams KB, Banderas JW, Catley D, Berkley-Patton J, et al. A randomized controlled trial examining the efficacy of motivational counseling with observed therapy for antiretroviral therapy adherence. AIDS Behav. 2013;17(6):1992–2001. doi:10.1007/s10461-013-0467-3.
68. Moyers TB, Miller WR, Hendrickson SM. How does motivational interviewing work? Therapist interpersonal skill predicts client involvement within motivational interviewing sessions. J Consult Clin Psychol. 2005;73(4):590–8. doi:10.1037/0022-006X.73.4.590.
69. Catley D, Harris KJ, Goggin K, Richter K, Williams K, Patten C, et al. Motivational Interviewing for encouraging quit attempts among unmotivated smokers: study protocol of a randomized, controlled, efficacy trial. BMC Public Health. 2012;12:456. doi:10.1186/1471-2458-12-456.
70. Drain PK, Losina E, Parker G, Giddy J, Ross D, Katz JN, et al. Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One. 2013;8(1):e55305. doi:10.1371/journal.pone.0055305.
71. Abaynew Y, Deribew A, Deribe K. Factors associated with late presentation to HIV/AIDS care in South Wollo ZoneEthiopia: a case-control study. AIDS Res Ther. 2011;8:8. doi:10.1186/1742-6405-8-8.
72. Kelly CA, Soler-Hampejsek E, Mensch BS, Hewett PC. Social desirability bias in sexual behavior reporting: evidence from an interview mode experiment in rural Malawi. Int Perspect Sex Reprod Health. 2013;39(1):14–21. doi:10.1363/3901413.
73. Peltzer K, Ramlagan S, Khan MS, Gaede B. The social and clinical characteristics of patients on antiretroviral therapy who are ‘lost to follow-up’ in KwaZulu-Natal, South Africa: a prospective study. SAHARA J. 2011;8(4):179–86. doi:10.1080/17290376.2011.9725002.
74. McNairy ML, Lamb MR, Abrams EJ, Elul B, Sahabo R, Hawken MP, et al. Use of a comprehensive HIV care cascade for evaluating HIV program performance: findings from 4 sub-Saharan African countries. J Acquir Immune Defic Syndr. 2015;70(2):e44–51. doi:10.1097/QAI.0000000000000745.
75. Plazy M, Orne-Gliemann J, Dabis F, Dray-Spira R. Retention in care prior to antiretroviral treatment eligibility in sub-Saharan Africa: a systematic review of the literature. BMJ Open. 2015;5(6):e006927. doi:10.1136/bmjopen-2014-006927.
76. Haberer JE, Musinguzi N, Boum 2nd Y, Siedner MJ, Mocello AR, Hunt PW, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in rural Uganda. J Acquir Immune Defic Syndr. 2015. doi:10.1097/QAI.0000000000000737.
77. Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav. 2015;19(5):794–801. doi:10.1007/s10461-014-0958-x.